Expert Interviews

Transitioning to the Real-World: Expert Experiences with Nasal Epinephrine Spray
June 10, 2025

A panelist discusses how shared decision-making between healthcare providers and patients should guide epinephrine device selection, with two real-world case studies demonstrating successful Neffy use in treating anaphylaxis with rapid symptom resolution.

A Fit for Many: Storage, Shelf Life, and Ideal Patients
June 10, 2025

A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.

Safety Solidified: Results of Oral Food Challenge Trials With Nasal Epinephrine Spray
June 10, 2025

A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.

Immediate Impact: Nasal Epinephrine Spray After Allergen Challenge
June 10, 2025

A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.

Nasal Epinephrine Spray: Review of Clinical Trial Results
June 10, 2025

A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.

An Opportunity for Innovation: Rethinking Unmet Needs in Epinephrine Administration
June 10, 2025

A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.

Bridging the Barriers: What is Preventing Patients From Using Epinephrine
June 10, 2025

A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.

Epinephrine First: The Proven First-Line Treatment for Anaphylaxis
June 10, 2025

A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.

Understanding Anaphylaxis: The Signs, Symptoms, and Burdens
June 10, 2025

A panelist discusses how anaphylaxis affects approximately 40 million people in the United States with severe systemic reactions involving multiple organ systems, leading to over 500,000 emergency room visits annually.

Chronic Hand Eczema: Clinical Insights and Future Directions from RAD 2025
June 10, 2025

RAD 2025: Explore expert insights on chronic hand eczema, its differences from atopic dermatitis, and emerging treatments in this informative video series.